Results 121 to 130 of about 418,673 (161)

Comparative effectiveness of insulin glargine, glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in veterans with type 2 diabetes. [PDF]

Diabetes Obes Metab
Shen J, Sarwal A, Singh R, Hartsell SE, Wei G, Nevers M, Christensen JC, Takyi A, Katkam N, Derington CG, Deshmukh VG, Boucher RE, Drakos SG, Greene T, Beddhu S.   +14 more
europepmc   +1 more source

Effectiveness and Safety of Insulin Glargine 300 U/ml in High-Risk Subgroups (Renal Impairment and Older Age ≥ 70 years) of Insulin-Naïve People with Type 2 Diabetes: A Post hoc Analysis of Real-World ATOS Study. [PDF]

Diabetes Ther
Tirosh A, Khan N, Vargas-Uricoechea H, Galstyan G, Al Shaikh AR, Makkar BM, Mabunay MA, Melas-Melt L, Pilorget V, Karalliedde J.   +9 more
europepmc   +1 more source

Clinical Outcomes of Switching U-100 Intermediate or Basal Insulin to U-200 Insulin Degludec or U-300 Insulin Glargine. [PDF]

J Prim Care Community Health
Rosario N, Hunger C, Pettijohn A, Whaley K, Pabon A, Hohl V, Asias-Dinh B, Gee J, Wollen J.   +8 more
europepmc   +1 more source

Budget impact analysis of insulin glargine vs. isophane protamine insulin treatment for patients with type-2 diabetes and severe hypoglycemia in Thailand. [PDF]

Front Public Health
Permsuwan U, Deerochanawong C.
europepmc   +1 more source

Insulin Access Enhancement in India: Expert Views on Integrating Interchangeable Biosimilar Insulin Glargine. [PDF]

Cureus
Prasanna Kumar KM, Chowdhury S, Bantwal G, Unnikrishnan AG, Kalra S, Aggarwal S, Singh AK, Pandit K, Shukla R, Vishwanathan V, Khobragade K, Sarda PS.   +11 more
europepmc   +1 more source

Analysis of patient characteristics and safety of insulin glargine U300 use in 21 359 patients with type-2 diabetes and chronic kidney disease: DPV registry study. [PDF]

Diabetes Obes Metab
Vijayan A, Lanzinger S, Forestier N, Hess G, Rottmann M, Wosch FJ, Seufert J, Holl RW, Bramlage P, DPV.   +9 more
europepmc   +1 more source

A dose titration protocol for once-daily insulin glargine 300 U/mL for the treatment of diabetes mellitus in dogs. [PDF]

J Vet Intern Med
Tardo AM, Fleeman LM, Fracassi F, Berg AS, Guarino AL, Gilor C.   +5 more
europepmc   +1 more source

Clinically meaningful improvements in treatment satisfaction in insulin-naïve people with type 2 diabetes post initiation of insulin glargine 300 U/mL: A post hoc analysis of real-world ATOS study. [PDF]

Diabetes Obes Metab
Snoek F, Galstyan G, Khan N, Tirosh A, Kesavadev J, Vargas-Uricoechea H, Baghous H, Mabunay MA, Grulovic N, Corp Dit Genti V, Msihid J, Harris S.   +11 more
europepmc   +1 more source

High-Concentration Insulin Glargine Overdose: Polyphasic Patterns of Blood Insulin Levels. [PDF]

Cureus
Tsunashima H, Takada H, Shiojima H, Yoneyama H, Hasegawa E.   +4 more
europepmc   +1 more source

Effectiveness and safety of insulin glargine 300 U/mL in insulin-naïve individuals according to diabetes duration: Results from the REALI European pooled data analysis. [PDF]

Diabetes Obes Metab
Gourdy P, Bonadonna RC, Mauricio D, Müller-Wieland D, Mauquoi C, Vera C, Bonnemaire M, Freemantle N.   +7 more
europepmc   +1 more source